 Mirati Therapeutics Inc NASDAQ: MRTX has announced results from a post hoc exploratory analysis of the Phase 2 study, MRTX-500 of sitravatinib combined with Bristol-Myers Squibb Cos NYSE: BMY Opdivo nivolumab. The trial included 68 patients with second or third-line non-squamous non-small cell lung cancer NSCLC who experienced clinical benefit on a prior checkpoint inhibitor CPI and subsequent disease progression. 